Who is the CEO of Corona Remedies Ltd?
- Answer Field
-
The CEO (Managing Director) of Corona Remedies Limited is Nirav K. Mehta, as per the company’s publicly available IPO documentation.
Corona Remedies Limited operates in the pharmaceutical formulations segment with a portfolio covering women’s healthcare, cardio-diabeto, pain management, urology, and several multispecialty categories. The company’s market presence is based on its distribution network across different regions in India and the manufacturing facilities located in Gujarat. Its portfolio includes a range of branded products used in multiple therapeutic areas, and the company engages with healthcare professionals through medical representatives. The company positions itself within the domestic branded formulations space and participates in selected therapeutic segments based on its product range and internal focus areas.
Investors can apply for the IPO through online platforms provided by registered intermediaries. The application process generally includes logging into the trading interface or bank application that offers the ASBA facility, selecting the IPO section, and choosing the relevant issue. The investor then enters bid details and confirms the application according to the available options. The funds remain blocked in the linked account until the allocation process is completed, as per the procedures followed by the intermediaries. The application steps may vary slightly depending on the intermediary interface, and applicants can refer to the official issue documents and disclosures for further procedural clarity.
For more details, visit the Corona Remedies Limited IPO page.
Details | Information |
IPO Date | December 8, 2025 to December 10, 2025 |
Issue Size | 61,71,101 shares (aggregating up to ₹655.37 Cr) |
Price Band | ₹1008 to ₹1062 per share |
Lot Size | 14 shares |
Listing At | BSE, NSE |
Undertake the Offer for Sale of Equity Shares of face value of 10 each aggregating up to 6,553.71 million by the Selling Shareholders
Achieve the benefits of listing the Equity Shares on the Stock Exchanges
Event | Date |
|---|---|
IPO Open Date | Mon, Dec 8, 2025 |
IPO Close Date | Wed, Dec 10, 2025 |
Tentative Allotment | Thu, Dec 11, 2025 |
Initiation of Refunds | Fri, Dec 12, 2025 |
Credit of Shares to Demat | Fri, Dec 12, 2025 |
Tentative Listing Date | Mon, Dec 15, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on Wed, Dec 10, 2025 |
₹1008 to ₹1062 per share
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 14 | ₹14,868 |
Retail (Max) | 13 | 182 | ₹1,93,284 |
S-HNI (Min) | 14 | 196 | ₹2,08,152 |
S-HNI (Max) | 67 | 938 | ₹9,96,156 |
B-HNI (Min) | 68 | 952 | ₹10,11,024 |
The Corona Remedies Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Access your trading account using the broker's app or website.
Go to the IPO section to view active IPO listings.
Locate Corona Remedies Limited IPO in the list of available IPOs and click the ‘Apply’ button.
Specify the number of shares (lot size: 14 shares) within the price band of ₹1008 to ₹1062 per share.
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Submit the application and monitor the allotment status to check if shares have been allocated to you.
Total Assets: Grew from ₹595.02 crore in FY23 to ₹1,012.38 crore as of June 2025.
Total income: Reached ₹348.56 crore in FY25.
Profit After Tax (PAT): Stood at ₹46.20 crore for June 2025.
Net Worth: Recorded at ₹607.02 crore in FY25.
Reserves and surplus: Stood at ₹545.86 crore in FY25.
EBITDA: Stood at ₹71.80 crore in June 2025.
Based on available financial disclosures, the company reported an increase in its asset base over the recent period, reflecting higher recorded holdings in its balance sheet.
Reported income for the period indicated growth in operational activity, supported by revenue from its product portfolio in various therapeutic segments.
Profit after tax filings showed a positive outcome during the stated period, indicating earnings generated from ongoing operations after accounting for expenses and taxes.
Net worth reported for the period reflected an improvement in shareholder equity, supported by internal financial reserves.
Disclosed reserves and surplus data indicated accumulation of retained earnings over time, contributing to overall financial strength.
The reported operating earnings data suggested the presence of earnings generated from core activities before accounting for interest, taxes, depreciation, and amortisation.
The recorded movement in financial indicators may be viewed as part of the company’s ongoing performance trend, based on filings available in public domain sources.
The company operates in a segment where product approvals, regulatory requirements, and compliance updates can influence business activities and timelines.
Demand patterns in therapeutic areas may vary due to changing prescription trends, healthcare access levels, and competition within the broader domestic market landscape.
The company’s focus on multiple therapeutic categories offers access to a wider patient base through its portfolio and regional coverage.
Expansion of branded formulations in selected therapeutic areas, supported by marketing networks and manufacturing facilities, may provide scope for continued market participation.
KPI | Values |
ROE | 27.50% |
ROCE | 41.32% |
Debt/Equity | 0.10 |
RoNW | 24.65% |
PAT Margin | 12.49% |
EBITDA Margin | 20.55% |
Price to Book Value | 10.71 |
Market Capitalisation | ₹6,495.20 Cr. |
Registrar | Lead Manager(s) |
|---|---|
Bigshare Services Pvt.Ltd. | JM Financial Ltd. |
Corona Remedies Ltd.
CORONA House, C – Mondeal Business Park
Near Gurudwara S. G. Highway
Thaltej
Ahmedabad, Gujarat, 380059
Phone: +91 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/
Corona Remedies Limited operates within the pharmaceutical formulations space and participates in selected therapeutic segments through its portfolio and distribution network. The company’s activities cover multiple treatment areas, supported by manufacturing facilities and engagement with healthcare professionals. The details related to the IPO, including timelines and offer structure, are available through the official documents published for the issue.
The application process can be completed through platforms that provide access to IPO bidding facilities, and applicants may review the information made available by authorised intermediaries. Investors can follow the stated procedure while ensuring that all steps are completed within the timelines indicated in the issue schedule. The details mentioned reflect disclosures available in the public domain and may be reviewed through exchange filings and offer documents for clarity.
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Corona Remedies IPO allotment status.
No result found
The CEO (Managing Director) of Corona Remedies Limited is Nirav K. Mehta, as per the company’s publicly available IPO documentation.
Corona Remedies operates in the pharmaceutical formulations sector, with a product portfolio spanning therapeutic areas such as women’s healthcare, cardio-diabetes, pain management, urology, and other multispecialty categories. The business model rests on manufacturing through established facilities, combined with a distribution and sales network across India, and a diversified product range across therapeutic areas. These features — a wide therapeutic spread, manufacturing capability, and distribution reach — may support continuity of operations over time, subject to market and regulatory conditions.
The total issue size of the Corona Remedies IPO has been set at ₹655.37 crore.
‘Pre-apply’ refers to placing an indication of interest for the IPO before the actual subscription window opens. This does not imply confirmation of allotment, but allows potential investors to submit their application in advance so that once the IPO opens, the bid is placed based on the pre-filled application parameters.
The lot size for the IPO is 14 shares, and that constitutes the minimum order quantity. For a retail investor at the upper price band, the minimum investment amount corresponds to that lot size.
Based on the available public disclosures, there is no widely reported governance issue or red flag associated with the company’s leadership or board structure. The publicly available IPO documentation identifies the promoters and leadership, without mention of regulatory or compliance concerns.
To apply for the IPO, an investor logs in to their trading account on a registered broker’s platform or through a bank supporting the ASBA (Application Supported by Blocked Amount) facility. Once logged in, the investor navigates to the IPO section, selects the Corona Remedies IPO, specifies the number of lots (multiples of 14 shares), enters the required UPI ID or payment mandate, and submits the bid before the cutoff time on the last subscription day. If the application is successful, funds remain blocked until share allotment or refund.
Yes. As with most IPOs in India, a Demat account is required to apply for the Corona Remedies IPO so that shares can be credited if allotted. This requirement is standard for IPO subscriptions routed through stock exchanges.
After the IPO subscription period closes and allotment is processed, investors can check the allotment status via the website of the registrar (Bigshare Services Pvt Ltd) or through the broker/trading platform. You may also receive notifications through email or the broker’s app. If the allotment is successful, shares will be credited to your Demat account on the scheduled share-credit date.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading